Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

British Journal of Cancer

Volumn 114, Issue 10, 2016, Pages 1084-1089

  Bowyer, S ^a,b   Prithviraj, P ^c,d   Lorigan, P ^e   Larkin, J ^f   McArthur, G ^g   Atkinson, V ^h   Millward, M ^b,i   Khou, M ^j   Diem, S ^f   Ramanujam, S ^k   Kong, B ^j   Liniker, E ^k   Guminski, A ^k   Parente, P ^l   Andrews, M C ^c,d   Parakh, S ^c   Cebon, J ^c,d   Long, G V ^k,m   Carlino, M S ^j,k,m   Klein, O ^c,d  

^a Rockingham General Hospital   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h GREENSLOPES PRIVATE HOSPITAL   (Australia)

ⁱ SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^j WESTMEAD HOSPITAL   (Australia)

^k MELANOMA INSTITUTE AUSTRALIA   (Australia)

^l BOX HILL HOSPITAL   (Australia)

^m UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

immune mediated adverse event; ipilimumab; metastatic melanoma; nivolumab; pembrolizumab

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BULLOUS PEMPHIGOID; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CLINICAL ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DIARRHEA; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENCEPHALITIS; FEMALE; HEPATITIS; HUMAN; HYPOPITUITARISM; HYPOTHYROIDISM; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; DRUG ADMINISTRATION; MELANOMA; METASTASIS; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84967185844     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.107     Document Type: Article

References (27)

1. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. (2010). Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 28(19): 3167-3175.
2. Bristol-Myer Squibb. (2013). Investigator Brochure NIVOLUMAB BMS-936558 MDX1106 Version 12.
3. Danlos FX, Pagès C, Roux J, Jebali M, Gornet JM, Bagot M, Lebbé C. (2015). Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. Melanoma Res. 25: 178-179.
4. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. (2015). Combination therapy with anti-CTLA-4, and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 194: 950-959.
5. Daud A, Ribas A, Robert C, Hodi S, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca RS, Patnaik A, Zarour HM, Kefford R, Lindia JA, Li XN, Ebbinghaus S, Kang SP, Hamid O. (2015). Long-Term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 33(Suppl): abstr 9005.
6. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Michael Y, Nichol G, White DE, Steinberg SM, Rosenberg SA. (2007). Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-Associated antigen-4 blockade. Clin Cancer Res. 13(1): 6681-6688.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer. 45(2): 228-247.
8. Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS. (2015). Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 21(4): 712-720.
9. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. (2013). Safety, and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 369(2): 134-144.
10. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363(8): 711-723.
11. Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner P, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA. (2013). Severe cutaneous, and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 1(6): 373-377.
12. Kaufman H, Lutzky J, Clark J, Margolin KA, Lawson DH, Amin A, Collichio FA, Pecora A, Urba WJ, Bennett KL, McDermott DF. (2013). Safety, and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020. J Clin Oncol (suppl; abstr 9050
13. Khoja L, Butler MO, Chappell MA, Hogg D, Joshua AM. (2015). Increased treatment-related toxicity subsequent to an anti-PD-1 agent. Curr Oncol. 22(4): 320-322.
14. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Schadendorf, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. (2015). Combined nivolumab, and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 373: 23-34.
15. Merck. (2014). KEYTRUDAs Prescribing Information http://.www.merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pdf
16. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372(4): 320-330.
17. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 372(26): 2521-2532.
18. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364(26): 2517-2526.
19. Rotte A, Bhandaru M, Zhou Y, Mcelwee KJ. (2015). Immunotherapy of melanoma: present options, and future promises. Cancer Metastasis Rev. 34(1): 115-128.
20. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. (2015). Pooled analysis of long-Term survival data from phase II, and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 33: 1889-1894.
21. Teng MWL, Ngiow SF, Ribas A, Smyth MJ. (2015). Classifying cancers based on T-cell infiltration, and PD-L1. Cancer Res. 75: 2139-2145.
22. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. (2014). Survival, durable tumor remission, and long-Term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 32(10): 1020-1030.
23. Weber JS, Yang JC, Atkins MB, Disis ML. (2015). Toxicities of immunotherapy for the practitioner. J Clin Oncol. 33(18): 2092-2100.
24. Weber JS, Kähler KC, Hauschild A. (2012). Management of immune-related adverse events, and kinetics of response with ipilimumab. J Clin Oncol. 30(21): 2691-2697.
25. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol. 31(34): 4311-4318.
26. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. (2013). Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 369(2): 122-133.
27. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 15(23): 7412-7420.